Practical Neurology

Treatment with was associated with greater reductions in monthly frequency than placebo in the phase 3 X-TOLE2 trial.
https://ow.ly/V57V50ZeJRX
American Academy of Neurology (AAN) Xenon Pharmaceuticals pvt.ltd

Investigational Antiseizure Medication Reduced Seizure Frequency in Phase 3 Focal Epilepsy Trial KEY TAKEAWAYS Treatment with azetukalner was associated with greater reductions in monthly seizure frequency than placebo in the phase 3 X-TOLE2 trial…

How should clinicians approach treatment selection in advanced ? Drs. Pinky Agarwal and John B. Sanderson (UW Medicine) discuss current device-aided and infusion therapies, highlighting factors that influence treatment choice, patient selection, and long-term management.

Read more: https://ow.ly/C0Mn50Zczas

International Parkinson and Movement Disorder Society American Academy of Neurology (AAN) AbbVie

Advanced Parkinson Disease: Treatment Approaches Advanced Parkinson Disease Treatment

Treatment with (Lundbeck US) was associated with reduced monthly days compared with placebo in the intravenous portion of the phase 2b clinical trial. Data presented at 2026
https://ow.ly/J4Se50Zcz90
American Headache Society® American Academy of Neurology (AAN)

Bocunebart Reduced Monthly Migraine Days in Phase 2b PROCEED Trial KEY TAKEAWAYS The intravenous portion of the phase 2b PROCEED trial met its primary efficacy end point, with bocunebart associated with a statistically …

Analyzing self-reported diaries provides practical lessons—with implications for outpatient care, clinical trials, & seizure risk forecasting.

Read a review from Dr. Daniel M. Goldenholz on what seizure diaries can teach us about management and research.
https://ow.ly/weiI50Zcz7X
Beth Israel Deaconess Medical Center American Epilepsy Society

How can health systems scale early detection while making the best use of clinical resources?

🎧 In an episode of Disease Deep Dive, Elyse Perweiler, RN, MPP and Tim MacLeod, PhD, discuss real-world lessons from implementing the Alzheimer’s Collaborative Healthcare System Preparedness US Early Detection Program at Rowan-Virtua School of Osteopathic Medicine.

Listen now: https://ow.ly/TtPm50ZcNUN

Davos Alzheimer's Collaborative Alzheimer's Association American Academy of Neurology (AAN)

Part II: Early Alzheimer Disease Detection through a Davos Alzheimer's Collaborative Initiative: Lessons from Real-World Implementation This episode explores the real-world implementation of the Davos Alzheimer’s Collaborative Healthcare System Preparedness (DAC-SP) US Early Detection Prog…

Can cell therapy address the compartmentalized that drives progressive ?

Drs. Sarah Conway & Kristin Galetta explore the rationale, early clinical data, and therapeutic potential of CAR T-cell approaches targeting pathogenic B cells and plasma cells in progressive .
https://ow.ly/3Gg850Zcz6Z
Stanford Medicine Harvard Medical School

Qulipta ( ) maintained a favorable safety profile and sustained efficacy through 156 weeks in people with chronic or episodic , according to final phase 3 extension study results presented at 2026.

https://ow.ly/fZ8Q50ZaGWf

American Headache Society® American Academy of Neurology (AAN) AbbVie

Qulipta Maintains Long-Term Safety Profile in 3-Year Migraine Prevention Extension Study KEY TAKEAWAYS Qulipta (atogepant) was generally safe and well tolerated through 156 weeks in people with chronic or episodic migraine. No new safety s…

The cover art for our April issue was created by Amy Bekier, Vice Chair of the FSHD Society. Living with disease, Amy has adapted by teaching herself to paint with her nondominant hand since losing dexterity in the other.
https://ow.ly/E7b550Zb91i

Progressive & in midlife should raise suspicion for more than normal .

A review by Drs. Minna Choi & Elina Zakin examines the clinical features, genetics, diagnostic workup, & management of muscular ( ), a rare and often underrecognized -related .

https://ow.ly/qOFJ50ZbsFE

American Association of Neuromuscular & Electrodiagnostic Medicine - AANEM American Academy of Neurology (AAN) NYU Langone Health

Oculopharyngeal Muscular Dystrophy: Key Clinical Features, Genetic Diagnosis, and Management Strategies oculopharyngeal muscular dystrophy

New from 2026: A network meta-analysis found (Axsome) was associated with greater odds of 2-hour pain freedom, sustained pain freedom, and lower rescue medication use compared with comparator for acute treatment.

https://ow.ly/7v3o50ZaH48

American Headache Society® American Academy of Neurology (AAN)

Symbravo Outperformed Gepants Across Multiple Acute Migraine End Points in Network Meta-Analysis KEY TAKEAWAYS Symbravo was associated with higher odds of 2-hour pain freedom and 2- to 24-hour sustained pain freedom compared with rimegepant, ubrog…